David Feifel, MD, PhD

Kadima Neuropsychiatry Institute, La Jolla, California

  • 12Articles
  • 44.4KReads
  • 1997–2026Active
  • 38Collaborators
  • 2.1KCitations

About

David Feifel, MD, PhD, is affiliated with the Kadima Neuropsychiatry Institute in La Jolla, California. He has contributed 12 articles to Psychiatrist.com from 1997 to 2026, focusing on topics such as depression, neurology, psychiatry, psychedelics, schizophrenia/schizoaffective disorders, and seizures. Frequent collaborators include Christine Y. Moutier, William Perry, Andrew J. Cutler, Ania Nowakowska, and Arthur Lazarus.

Publications

JCP
The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD
Podcast

The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD

January 13, 2026

Dr. David Feifel discusses psilocybin's breakthrough potential for treatment-resistant depression, the psychedelic renaissance, and preparing for a new era in psychiatry.
,
JCP
Maintenance of Antidepressant Effect After 1 Dose of Psilocybin
Original Research

Maintenance of Antidepressant Effect After 1 Dose of Psilocybin

March 3, 2025

Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg.
, , , et al
JCP
Letter to the Editor

Roles of TMS Treatment Team Members

February 21, 2018

Read this article to learn more about the roles and qualifications of TMS Treatment team members.
, ,
JCP
Original Research

Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

January 25, 2011

, , , et al
JCP
Original Research

Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder: A Placebo- and Duloxetine-Controlled Study

April 7, 2009

, , , et al
JCP
Letter to the Editor

Dosing of Divalproex Extended Release

July 16, 2007

JCP
Original Research

A Systematic Review of Modafinil: Potential Clinical Uses and Mechanisms of Action

April 15, 2006

,
JCP
Original Research

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

March 1, 2004

, , , et al
JCP
Letter to the Editor

Retraction

February 1, 2002

, ,
JCP
Original Research

Safety and Tolerability of a Rapidly Escalating Dose-Loading Regimen for Risperidone [RETRACTED ARTICLE]

December 31, 2000

, ,
JCP
Article

Rationale and Guidelines for the Inpatient Treatment of Acute Psychosis

December 30, 2000

JCP
Original Research

Iron Overload Among a Psychiatric Outpatient Population

February 15, 1997

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe